Bicyclic unsaturated tertiary amine compounds
1 Assignment
0 Petitions
Accused Products
Abstract
A bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. The compound has the following formula (I):
- wherein A represents pyrrole or pyrazole, R1 represents an aryl group or a heteroaryl group which may be substituted, R2 represents a heteroaryl group which may be substituted, and R3 represents an indolizine group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
Citations
67 Claims
-
1. A compound of the following formula (1):
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)
-
2. A compound according to claim 1, wherein R1 is an unsubstituted aryl group;
- or an aryl group substituted by at least one group selected from the group consisting of substituent group α and
substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- or an aryl group substituted by at least one group selected from the group consisting of substituent group α and
-
3. A compound according to claim 1, wherein R1 is an unsubstituted phenyl, an unsubstituted naphthyl, or a phenyl or a naphthyl substituted by at least one group selected from the group consisting of substituent group α
- and substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- and substituent group β
-
4. A compound according to claim 1, wherein R1 is an unsubstituted phenyl or a phenyl substituted by at least one group selected from substituent group α
-
1 and substituent group β
1, substituent group α
1 is selected from the group consisting of a cyano group, a halogen atom, a lower alkoxy group, a halogeno lower alkoxy group and a group of formula;
—
NRaRb, wherein one of Ra and Rb represents a hydrogen atom or a lower alkyl group, and the other represents a hydrogen atom, a lower alkyl group or an aralkyl group,substituent group β
1 is selected from the group consisting of a lower alkyl group, a halogeno lower alkyl group, a hydroxy—
lower alkyl group, a nitro—
lower alkyl group, an amino—
lower alkyl group, a lower alkylamino—
lower alkyl group, a di(lower alkyl)amino—
lower alkyl group and an aralkylamino—
lower alkyl group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
1 and substituent group β
-
5. A compound according to claim 1, wherein R1 is an unsubstituted phenyl or a phenyl substituted by at least one group selected from the group consisting of a cyano group, a halogen atom, a lower alkoxy group, a halogeno lower alkyl group and a halogeno lower alkoxy group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
6. A compound according to claim 1, wherein R1 is phenyl, 4-fluorophenyl, 3-fluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3,4,5-trifluorophenyl, 3-chloro-4-fluorophenyl, 3-difluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 3-trifluoromethylphenyl, 3-methoxyphenyl, 3-cyanophenyl or 4-fluoro-3-methoxyphenyl, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof,
-
7. A compound according to claim 1, wherein R1 is phenyl, 4-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 3,4-difluorophenyl, 3,4,5-trifluorophenyl, 3-chloro-4-fluorophenyl, 3-difluoromethoxyphenyl, 3-trifluoromethylphenyl, 3-methoxyphenyl, 3-cyanophenyl or 4-fluoro-3-methoxyphenyl, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
8. A compound according to claim 1, wherein R1 is phenyl, 4-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 3,4-difluorophenyl, 3-chloro-4-fluorophenyl or 3-trifluoromethylphenyl, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
9. A compound according to any one of claims 1 to 8, wherein R2 is an unsubstituted 5- or 6-membered heteroaryl group containing 1 or 2 nitrogen atoms;
- or a 5- or 6-membered heteroaryl group containing 1 or 2 nitrogen atoms substituted by at least one group selected from the group consisting of substituent group α and
substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- or a 5- or 6-membered heteroaryl group containing 1 or 2 nitrogen atoms substituted by at least one group selected from the group consisting of substituent group α and
-
10. A compound according to any one of claims 1 to 8, wherein R2 is unsubstituted pyridyl, unsubstituted pyrimidinyl, or pyridyl or pyrimidinyl substituted by at least one group selected from the group consisting of substituent group α
- and substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- and substituent group β
-
11. A compound according to any one of claims 1 to 8, wherein R2 is an unsubstituted 4-pyridyl, an unsubstituted 4-pyrimidinyl, or 4-pyridyl or 4-pyrimidinyl substituted by at least one group selected from the group consisting of substituent group α
- and substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- and substituent group β
-
12. A compound according to any one of claims 1 to 8, wherein R2 is an unsubstituted 4-pyridyl, an unsubstituted 4-pyrimidinyl, or 4-pyridyl or 4-pyrimidinyl wherein the 2-position thereof is substituted by one group selected from the group consisting of substituent group α
- and substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- and substituent group β
-
13. A compound according to any one of claims 1 to 8, wherein R2 is an unsubstituted 4-pyridyl, an unsubstituted 4-pyrimidinyl, or 4-pyridyl or 4-pyrimidinyl wherein the 2-position is substituted by one group selected from the group consisting of methoxy, amino, methylamino, benzylamino and α
- -methylbenzylamino, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
14. A compound according to any one of claims 1 to 13, wherein R4 is a group independently selected from a hydrogen atom;
- a lower alkyl group;
a group of formula;
—
NRα
Rβ
, wherein Rα
and Rβ
are the same or different and each represents a hydrogen atom, a lower alkylsulfonyl group or a lower aliphatic acyl group;
an unsubstituted aryl group and an aryl group substituted by at least one group selected from the group consisting of substituent group α and
substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- a lower alkyl group;
-
15. A compound according to any one of claims 1 to 13, wherein R4 is a group independently selected from the group consisting of a hydrogen atom, a methyl group, an ethyl group, a propyl group, a butyl group, an amino group, an unsubstituted phenyl group and a phenyl group substituted by at least one group selected from the group selected from substituent group α
- and substituent group β
, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
- and substituent group β
-
16. A compound according to any one of claims 1 to 13, wherein R4 is a methyl group, an ethyl group, a propyl group, a butyl group, a phenyl group;
- or a phenyl group substituted by 1 or 2 substituents selected from the group consisting of a hydroxyl group, a halogen atom, a lower acyloxy group, a lower alkoxy group, a halogeno lower alkoxy group, a lower alkyl group and a halogeno lower alkyl group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
17. A compound according to any one of claims 1 to 13, wherein R4 is a methyl group, an ethyl group, a propyl group, a butyl group, an unsubstituted phenyl group, or a phenyl group substituted by 1 or 2 substituents selected from the group consisting of a hydroxyl group, a fluorine atom, a chlorine atom, a bromine atom, a formyloxy group, an acetoxy group, a propionyloxy group, a butyryloxy group, an isobutyryloxy group, a valeryloxy group, an isovaleryloxy group, a pivaloyloxy group, a methyl group, an ethyl group, a propyl group, a butyl group, a tert-butyl group, a difluoromethyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a tert-butoxy group, a difluoromethoxy group and a trifluoromethoxy group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
18. A compound according to any one of claims 1 to 13, wherein R4 is a methyl group, an ethyl group, a propyl group, a butyl group, an unsubstituted phenyl group;
- or a phenyl group substituted by 1 or 2 substituents selected from the group consisting of a hydroxyl group, a fluorine atom, a chlorine atom, an acetyloxy group, a methyl group, an ethyl group, a methoxy group and an ethoxy group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
19. A compound according to any one of claims 1 to 18, wherein A is pyrrole, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
20. A compound according to anyone of claims 1 to 19, wherein the compound of formula (I) is a compound represented by any one of the following formulae:
-
21. A compound according to any one of claims 1 to 19, wherein the compound of formula (I) is a compound represented by the following formula:
-
22. A compound according to any one of claims 1 to 18, wherein. A is pyrazole, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
23. A compound according to any one of claims 1 to 18 and 22, wherein the compound of formula (I) is a compound represented by any one of the following formulae:
-
24. A compound according to any one of claims 1 to 18 and 22, wherein the compound of formula (I) is a compound represented by the following formula:
-
25. A compound according to claim 1, wherein the compound of formula (I) is a compound represented by the following formula:
-
26. A compound according to claim 25, wherein R1 is a phenyl group, a fluorophenyl group, a chlorophenyl group, a difluorophenyl group, a chlorofluorophenyl group or a trifluoromethylphenyl group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
27. A compound according to claim 25, wherein R1 is a fluorophenyl group and R3 is a group of the following formula:
-
28. A compound according to claim 25, wherein R1 is a chlorofluorophenyl group and R3 is a group of the following formula:
-
29. A compound according to claim 1, wherein the compound of formula (I) is a compound represented by the following formula:
-
30. A compound according to claim 29, wherein R1 is a 4-fluorophenyl group or a trifluoromethylphenyl group and
R4 is a fluorophenyl group, a 4-methylphenyl group or a methoxyphenyl group, or a pharmacologically acceptable-salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof. -
31. A compound according to claim 1, wherein the compound is a compound selected from the group consisting of
4-[(2S,8aS)-2-butyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole, 2-(4-fluorophenyl)-4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(4-fluorophenyl)-4-[(2R,8aS)-2-(4-fluorophenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(3,4-difluorophenyl)-4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(4-fluorophenyl)-4-[(2S,8aS)-2-(4-methylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(3-chlorophenyl)-4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 4-[(2S,8aS)-2-(4-methylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole, 2-(4-fluorophenyl)-4-[(2S,8aS)-2-(4-methoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole, 2-phenyl-4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 4-[(2S,8aS)-2-(4-ethylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole, 4-[(2S,8aS)-2-(4-ethylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-2-(3,4-difluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole and 2-(3-chloro-4-fluorophenyl)-4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof. -
32. The compound according to claim 1, wherein the compound of formula (I) is a compound represented by any one of the following formulae:
-
33. A compound according to claim 32, wherein R1 is a phenyl group, a fluorophenyl group or a chlorofluorophenyl group, and
R4 is a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, an unsubstituted phenyl group, a phenyl substituted by an alkyl group having from 1 to 3 carbon atoms, or a phenyl group substituted by an alkoxy group having from 1 to 3 carbon atoms, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof. -
34. A compound according to claim 1, wherein the compound is a compound selected from the group consisting of:
-
3-[(2S,8aS)-2-butyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-5-(4-fluorophenyl)-4-(pyridin-4-yl) pyrazole, 5-(4-fluorophenyl)-3-[(2S,8aS)-2-propyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-4-(pyridin-4-yl) pyrazole, 5-(4-fluorophenyl)-3-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-4-(pyridin-4-yl) pyrazole, 5-(4-fluorophenyl)-3-[(2S,8aS)-2-(4-methylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]4-(pyridin-4-yl)pyrazole and 5-(3-chloro-4-fluorophenyl)-3-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-4-(pyridin-4-yl)pyrazole, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
-
35. A compound according to claim 1, wherein the compound of formula (I) is a compound represented by the following formula:
-
36. A compound according to claim 35, wherein R1 is a methoxyphenyl group or a fluoro(methoxy)phenyl group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
37. A compound according to claim 1, wherein the compound of formula (I) is a compound represented by the formula:
-
38. A compound according to claim 39, wherein R1 is a 4-fluorophenyl group, and
R4 is a 3-methylphenyl group, an ethylphenyl group, a butylphenyl group, a 3-methoxyphenyl group, an ethoxyphenyl group, a hydroxyphenyl group or an acetoxy group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof. -
39. A compound according to claim 1, wherein the compound of formula (I) is a compound represented by the formula:
-
40. A compound according to claim 39, wherein R1 is a chlorophenyl group or a difluorophenyl group and
R4 is a methylphenyl group, an ethylphenyl group, a propylphenyl group, an isopropylphenyl group, a butylphenyl group, a methoxyphenyl group, an ethoxyphenyl group, a propoxyphenyl group or a hydroxyphenyl group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or other pharmacologically acceptable derivatives thereof. -
41. The compound according to claim 1, wherein the compound is a compound selected from the group consisting of:
-
2-(4-fluorophenyl)-4-[(2S,8aS)-2-(3-methylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(3,4-difluorophenyl)-4-[(2S,8aS)-2-(4-methylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(3-chlorophenyl)-4-[(2S,8aS)-2-(4-methylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(3,4-difluorophenyl)-4-[(2S,8aS)-2-(4-methoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(4-fluorophenyl)-4-[(2S,8aS)-2-(3-methoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(3-chlorophenyl)-4-[(2S,8aS)-2-(4-methoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 4-[(2S,8aS)-2-(4-ethoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole, 2-(3,4-difluorophenyl)-4-[(2S,8aS)-2-(3-methoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(4-fluorophenyl)-4-[(2S,8aS)-2-(4-hydroxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 4-[(2S,8aS)-2-(4-acetoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole, 2-(3,4-difluorophenyl)-4-[(2S,8aS)-2-(3-hydroxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(4-fluoro-3-methoxyphenyl)-4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole, 2-(3-methoxyphenyl)-4-[(2S,8aS)-2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole), 4-[(2S,8aS)-2-(4-ethoxyphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-2-(3,4-difluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole, 2-(4-fluorophenyl)-4-[(2S,8aS)-2-(3,4-dimethylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole and 2-(3,4-difluorophenyl)-4-[(2S,8aS)-2-(3,4-dimethylphenyl)-1,2,3,5,6,8a-hexahydroindolizin-7-yl]-3-(pyridin-4-yl)-1H-pyrrole or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
-
42. A pharmaceutical composition comprising as an active ingredient a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41 in combination with a pharmacologically acceptable carrier, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
43. A pharmaceutical composition according to claim 42, wherein the composition is for inhibiting the production of inflammatory cytokines.
-
44. A pharmaceutical composition according to claim 42, wherein the composition is an antifebrile/analgesic, an anti-inflammatory agent or an anti-virus agent.
-
45. A pharmaceutical composition according to claim 42, wherein the composition is for preventing or treating rheumatoid arthritis.
-
46. A pharmaceutical composition according to claim 42, wherein the composition is for preventing or treating osteoarthritis.
-
47. A pharmaceutical composition according to claim 42, wherein the composition is for preventing or treating septicaemia.
-
48. A pharmaceutical composition according to claim 42, wherein the composition is for preventing or treating diabetes.
-
49. A pharmaceutical composition according to claim 48, wherein the diabetes is I type diabetes.
-
50. A pharmaceutical composition according to claim 42, wherein the composition is for preventing or treating psoriasis, Crohn'"'"'s disease, ulcerative colitis or hepatitis.
-
51. A method for inhibiting the production of inflammatory cytokines, which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
52. The method according to claim 51, wherein the mammal is a human being.
-
53. A method for treating or removing pain and/or inflammation which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
54. The method according to claim 53, wherein the mammal is a human being.
-
55. A method for preventing or treating rheumatoid arthritis which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
56. The method according to claim 55, wherein the mammal is a human being.
-
57. A method for preventing or treating osteoarthritis which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
58. The method according to claim 57, wherein the mammal is a human being.
-
59. A method for preventing or treating septicaemia which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
60. The method according to claim 59, wherein the mammal is a human being.
-
61. A method for preventing or treating diabetes which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
62. The method according to claim 61, wherein the mammal is a human being.
-
63. The method according to claim 61, wherein the diabetes is I type diabetes.
-
64. A method for preventing or treating psoriasis, Crohn'"'"'s disease, ulcerative colitis or hepatitis which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
65. The method according to claim 64, wherein the mammal is a human being.
-
66. A method for preventing or treating a viral disease which comprises administering to a mammal a pharmacologically effective amount of a compound as set forth in any one of claims 1 to 41, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
-
67. The method according to claim 66, wherein the mammal is a human being.
-
2. A compound according to claim 1, wherein R1 is an unsubstituted aryl group;
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSankyo Company Limited (Daiichi Sankyo Company Limited)
-
Original AssigneeSankyo Company Limited (Daiichi Sankyo Company Limited)
-
InventorsNakao, Akira, Aoki, Kazumasa, Kimura, Tomio, Nagasaki, Takayoshi, Ohkawa, Nobuyuki
-
Application NumberUS11/039,423Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current514/306CPC Class CodesA61K 31/4745 condensed with ring systems...C07D 401/04 directly linked by a ring-m...C07D 401/12 linked by a chain containin...C07D 401/14 containing three or more he...C07D 403/04 directly linked by a ring-m...C07D 403/14 containing three or more he...C07D 409/14 containing three or more he...C07D 455/02 containing not further cond...C07D 471/04 Ortho-condensed systems